Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Interest Expenses (2022 - 2025)

Pliant Therapeutics has reported Interest Expenses over the past 4 years, most recently at $136000.0 for Q4 2025.

  • Quarterly Interest Expenses fell 83.69% to $136000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Mar 2026, down 47.9% year-over-year, with the annual reading at $2.6 million for FY2025, 15.38% down from the prior year.
  • Interest Expenses was $136000.0 for Q4 2025 at Pliant Therapeutics, down from $815000.0 in the prior quarter.
  • Over five years, Interest Expenses peaked at $877000.0 in Q3 2024 and troughed at $136000.0 in Q4 2025.
  • The 4-year median for Interest Expenses is $321000.0 (2023), against an average of $509466.7.
  • Year-over-year, Interest Expenses soared 176.66% in 2024 and then plummeted 83.69% in 2025.
  • A 4-year view of Interest Expenses shows it stood at $317000.0 in 2022, then rose by 1.26% to $321000.0 in 2023, then soared by 159.81% to $834000.0 in 2024, then plummeted by 83.69% to $136000.0 in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Interest Expenses are $136000.0 (Q4 2025), $815000.0 (Q3 2025), and $809000.0 (Q2 2025).